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Abstract
Background: Obstetrics and gynaecology have seen rapid growth in the development of new tests with research
on these tests presented as diagnostic accuracy studies. To avoid errors in judgement it is important that the
methodology of these studies is such that bias is minimised. Our objective was to determine the methodological
quality of test accuracy studies in obstetrics and gynaecology using the Quality Assessment of Diagnostic Accuracy
Studies (QUADAS) checklist and to assess sources of bias.
Methods: A prospective protocol was developed to assess the impact of QUADAS on ten systematic reviews
performed over the period 2004-2007.We investigated whether there was an improvement in study quality since
the introduction of QUADAS, whether a correlation existed between study sample size, country of origin of study
and its quality. We also investigated whether there was a correlation between reporting and methodological
quality and by the use of meta-regression analyses explored for items of quality that were associated with bias.
Results: A total of 300 studies were included. The overall quality of included studies was poor (> 50% compliance
with 57.1% of quality items). However, the mean compliance with QUADAS showed an improvement post-
publication of QUADAS (54.9% versus 61.4% p = 0.002). There was no correlation with study sample size.
Gynaecology studies published from the United States of America showed higher quality (USA versus Western
Europe p = 0.002; USA versus Asia p = 0.004). Meta-regression analysis showed that no individual quality item had
a significant impact on accuracy. There was an association between reporting and methodological quality (r = 0.51
p < 0.0001 for obstetrics and r = 0.56 p < 0.0001 for gynaecology).
Conclusions: A combination of poor methodological quality and poor reporting affects the inferences that can be
drawn from test accuracy studies. Further compliance with quality checklists is required to ensure that bias is
minimised.
Background
Obstetrics and gynaecology have seen rapid growth in
the development of new tests [1-4]. For instance, tests
designed to detect small for gestational age fetuses and
to improve the staging of cancers have grown in recent
years [5-9]. A key aspect of research on these is pre-
sented in the form of test accuracy studies [10], which
generate a comparison of measurements made by an
index test against those of an accepted reference
standard test - the “gold standard”. These comparisons
enable an assessment of the accuracy of an index test,
which are often expressed as sensitivity and specificity,
likelihood ratios (LRs), diagnostic odds ratio (DOR), or
area under a receiver-operator characteristics curve [11].
Using this information enables readers to make judge-
ments relating to the potential suitability of new tests
for clinical practice.
To avoid errors in judgement it is important that the
methodology of the study is such that bias is minimised.
The reporting of the study should allow for the detec-
tion of any biases by providing a complete and transpar-
ent description of the study participants, methodology
and results. Guidelines for the reporting of other study
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types have widely been accepted e.g. CONSORT [12] for
randomised control trials and QUOROM [13] and
MOOSE [14] for systematic reviews. The recommended
format for reporting primary accuracy evaluations of
tests is called Standards for Reporting of Diagnostic
Accuracy - STARD [15]. When studies of this type are
incorporated in systematic reviews, assessment of their
methodological quality is necessary. This allows metho-
dological flaws, which can lead to bias, and sources of
variation that might lead to heterogeneity, to be identi-
fied. An evidence based methodological quality assess-
ment tool has been developed called Quality Assessment
of Diagnostic Accuracy Studies (QUADAS) [16]. The
need for quality appraisal of included studies in sys-
tematic review has been recognised for many years how-
ever, how deficiencies in study quality should be
addressed in meta-analysis is not as clear [17,18].
The QUADAS initiative provides an assessment tool
for the quality of test accuracy studies, as is required
when using these studies in systematic reviews. It com-
bines empirical evidence and expert opinion into a
checklist of 14 quality items. As these quality items
should be adhered to and then reported in a study, they
are directly, and indirectly duplicated in the STARD
checklist. Although gaps in reporting of quality item
themselves do not necessarily mean that the methodolo-
gical quality is poor, interpretation is made difficult [19].
The use of one standard checklist for assessment of
study quality in all diagnostic reviews should allow clini-
cians to make comparable assessment of different stu-
dies. Where previous studies have attempted to assess
methodological or reporting quality of test accuracy stu-
dies, a strong relationship has been found between var-
ious quality items and test accuracy results [20,21]. This
study aims to assess the impact of the QUADAS initia-
tive, on test accuracy studies, in antenatal screening and
gynaecologic oncology.
Methods
A prospective protocol was developed to assess the
impact of QUADAS on ten systematic reviews per-
formed over the period 2004-2007. These systematic
reviews were selected as they were all performed by the
authors, according to prospective protocols and recom-
mended methodology, with prospective assessment of
methodological quality using the QUADAS checklist
thus uniform assessment could be ensured. We included
reviews of minimal and non invasive tests to determine
the lymph node status in gynaecological cancers [5-7]
and reviews of Down’s serum screening markers and
uterine artery Doppler to predict small for gestational
age fetuses in obstetrics [8,9]. The checklist was also tai-
lored to take into account the nature of each review e.g.
the nature of the index test (the tailored checklists are
available as appendices to the published reviews). We
addressed the following questions: What is the quality
of studies in these fields? Is there a difference in quality
between studies in Obstetrics and Gynaecology? Did the
introduction of QUADAS improve quality? Does study
size correlate with quality? Is there a geographical pat-
tern to quality? Is there a relationship between compli-
ance with STARD and QUADAS? Which quality items
are associated with bias?
The QUADAS checklist was applied to each of the
studies included in the reviews with the quality item
being determined as either present, absent, unclear or
not applicable (additional file 1). All studies were
assessed in duplicate by TJS and RKM, where there was
disagreement this was resolved by consensus with a
third reviewer (KSK). All studies were also assessed for
reporting quality using the STARD checklist. Results of
individual studies were summarized in two by two tables
from which the DOR was calculated as a measure of
diagnostic accuracy [11]. DOR is the odds of a positive
result in a diseased person relative to the odds of a posi-
tive result in a non diseased person. In the case of zero
entities in the two by two tables 0.5 was added to the
cells to enable calculation of DOR [22]. In the event
that several tests had been applied to the same patient,
the results including the largest number of patients were
used in this study or where there was no difference, one
index test was selected at random, this ensured patients
were only included once.
The percentage compliance of studies with QUADAS
items was compared between both specialties, before
and after the introduction of QUADAS, using the
unpaired t test to assess the effect of QUADAS on the
methodological quality of studies. With the publication
of QUADAS in 2003 the assumption was made that all
studies published pre 2005 were published without the
benefit of this directorate.
We examined the relationship between sample size
and compliance with QUADAS using Spearman’s rank
correlation coefficient (Rho). Kruskal Wallis was used to
investigate any relationship between geographical distri-
bution and reporting quality. The country of origin of a
study was determined by the country of the correspond-
ing author. Where a significant result was found, pair-
ways comparison was made using Conover Inman
procedure. Countries were grouped depending on the
number of articles published and the mean journal
impact factor and adjusted for gross domestic product
and population, based on previous publication [23].
Where there was a large disparity in number of studies
per geographical area, some studies were re grouped to
avoid large differences in group size and potentially
spurious results. For obstetric reviews geographical areas
were Oceania, USA, Canada, Asia, Japan, Africa, Eastern
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Europe and Western Europe and for gynaecology studies
there were no studies from Oceania or Canada, but
Latin America was added.
If the standard of reporting of a study is poor then
this can potentially limit the assessment of the quality of
study design. To investigate the relationship between
reporting and methodological quality, the studies’ com-
pliance with STARD and QUADAS was compared using
Spearman correlation coefficient. The difference in com-
pliance with the two checklists between obstetrics and
gynaecology was assessed using unpaired t test.
The final analysis performed was a meta-regression
analysis to assess which quality items were associated
with bias. Multiple logistic regression models were
adjusted to test the effect of individual QUADAS quality
items on diagnostic accuracy, measured as the diagnos-
tic odds ratio (DOR) [24]. This methodology [25] has
been used successfully in demonstrating empirically the
effect of bias related to methodological flaws in clinical
trials [26-28] and in diagnostic studies [29]. The depen-
dent variable in each logistic model was a binary vari-
able representing disease status (diseased verses non
diseased) from each meta-analysis. The independent
variables included a variable representing test threshold
(i.e. the sum of logits of sensitivity and 1-specificity); a
binary variable for test result (positive versus negative);
indicator variables to control for the effect of the pri-
mary studies and the “QUADAS item (dichotomized as
Yes versus all other) by test result” interaction terms to
analyze its association with estimates of diagnostic accu-
racy. The estimated effect of a quality characteristic on
average diagnostic accuracy is given by the coefficient of
this latter variable whose exponentiation gives the diag-
nostic performance (DOR) of studies failing to satisfy
the methodological criterion relative to its performance
in studies with that feature. This is the Relative Diag-
nostic Odds Ratio (RDOR). If this ratio is greater than 1
then the accuracy of studies without that feature overes-
timates the diagnostic performance compared to studies
with that feature. Only meta-analyses that contained
studies with and without the characteristic could contri-
bute to this estimate. We used the RDOR as the sum-
mary measure of accuracy and dependant variable in the
analyses as it is useful as a single indicator of test
performance.
In the initial analysis those quality items coded as
unclear and not applicable were excluded. For all of the
above analysis, due to the uncertainty of whether report-
ing items coded as unclear represented methodological
failure, sensitivity analysis was performed excluding
unclear as a code and adding it to the not reported
group for all comparisons. Similarly sensitivity analysis
was also performed to assess the effect of those items
assessed as not applicable, with their initial exclusion in
the analysis and then addition as if they were reported i.
e. “yes” so as not to penalise studies which had a larger
number of not applicable items and would therefore
potentially have a seemingly lower compliance with
QUADAS.
Results
A total 300 studies (195 obstetric and 105 gynaecologic
studies) from ten systematic reviews were identified and
included in this study. 85.6% (167/195) of the obstetric
studies and 93% (98/105) of the gynaecological studies
were published prior to the QUADAS initiative. The
overall percentage compliance with individual quality
items is shown in figure 1. The included studies for
both reviews complied adequately > 50% of the time for
57.1% (8/14) of the items assessed. Items where quality
was uniformly poor (both obstetrics and gynaecology <
50%) were an adequate description of the performance
of the reference standard, reporting whether the refer-
ence test results were interpreted blind to the index test
results and whether clinical data was available at the
time of test interpretation. In addition for obstetric stu-
dies only 44.1% used an appropriate reference standard
and only in 55.3% of studies did all patients receive the
same reference standard. This reflects the nature of the
poor quality of reference standards employed in the
obstetric reviews and the lack of an accepted “gold stan-
dard” for the conditions under investigation (fetal
growth restriction). In only 19% of gynaecology studies
was the index test interpretation blind, reflecting the
nature of the tests assessed in these reviews.
There was an improvement in the mean compliance
with quality items after publication of the QUADAS
checklist (54.9% versus 61.4%) which reached statistical
significance (0 = 0.002); this was mainly due to an
improvement in gynaecology studies (54.4% versus
70.4%) rather than obstetrics (55.5% versus 59.2%). Ana-
lysis of the correlation between sample size and QUA-
DAS revealed no correlation for obstetrics (Rho = 0.14,
p = 0.06) or gynaecology (Rho = -0.047, p = 0.64). For
these analyses sensitivity analysis as described in the
methods section showed no significant difference.
The mean compliance with QUADAS according to
country of publication of study is shown in table 1.
Investigation in to the relationship between geographical
area of publication with QUADAS showed no associa-
tion between compliance and area for the primary ana-
lysis in either obstetrics (p = 0.73) or gynaecology (p =
0.12). However for gynaecology, sensitivity analysis
revealed a positive correlation between the compliance
with QUADAS when those items considered not applic-
able were included with those items that had been
reported (p = 0.05). Further pair-wise comparison using
Conover Inman procedure showed that studies from the
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USA had greater compliance (USA versus Western Eur-
ope p = 0.002; USA versus Asia p = 0.004).
In the meta regression analysis for gynaecology studies
initially only one of the QUADAS items had a signifi-
cant impact on the diagnostic accuracy of the studies
and that was whether a manuscript explained the
withdrawals from a study. In those studies where with-
drawals were not explained there was an overestimation
in the accuracy of the test (p = 0.005). However, in the
majority of studies this quality item was coded as ‘not
applicable’, thus when the analysis was repeated with
these studies removed, adherence to this quality item
also failed to have an impact on test accuracy. In the
meta-regression for obstetrics, only QUADAS item 3
(appropriate reference standard) had a marginal impact
on diagnostic accuracy (p = 0.05), so that studies in
which an inappropriate reference standard was used
overestimated the diagnostic accuracy by 10%. The
results are illustrated in figure 2.
All included papers were assessed for reporting stan-
dard and overall this was poor. The included obstetric
studies reported adequately > 50% of the time for 62.1%
(18/29) of the items as assessed in this review and for
gynaecology 51.7% (15/29). Only 2 obstetric papers (no
gynaecology papers) used a STARD flow diagram and
these were published after the publication of the
STARD statement. There was significant correlation
between the percentage compliance of studies with
STARD and QUADAS checklists for obstetrics (Rho =
0.51, p = < 0.0001) and gynaecology (Rho 0.56, p = <
Q
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Figure 1 Percentage compliance with individual QUADAS criteria for included test accuracy studies in obstetrics and gynaecology.
Table 1 Mean percentage compliance of studies with
QUADAS according to geographical area of publication
Area of
publication
Mean percentage
compliance obstetrics
(%)
[number of studies]
Mean percentage
compliance gynaecology
(%)
[number of studies]
Africa 50% [1] No studies
Asia 56.3% [8] 57.7% [12]
Canada 55.1% [7] No studies
Eastern
Europe
52.7% [16] 58.6% [5]
Japan 55.1% [7] 58.9% [4]
Latin America No studies 57.1% [2]
Oceania 61.6% [8] 35.6% [1]
United States
of America
55.2% [44] 50.5% [1]
Western
Europe
55.7% [104] 57.5% [52]
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0.0001) which is illustrated in figure 3. This figure shows
that when studies had a higher standard of reporting
they also had a higher standard of methodology.
Discussion
This study showed that there was an improvement in
the methodological quality of test accuracy studies in
gynaecology cancer since the introduction of the QUA-
DAS initiative but not for obstetrics. Unsurprisingly, due
to the overlap in quality items between the two check-
lists there was a positive correlation between compliance
with STARD and QUADAS. Sample size showed no
correlation with compliance. Studies from the USA had
greater compliance with QUADAS for gynaecology stu-
dies. No correlation with geographical area was seen for
obstetrics. Meta regression did not show any significant
correlation between compliance with QUADAS item
and test accuracy.
The strengths of our study lie in the large number of
included studies and meta-analyses, the continuity in
assessment using the same two reviewers throughout
and the use of tailored checklists to take into account
the differences in studies in gynaecological oncology and
obstetrics (e.g. the utilisation of the not applicable cate-
gory). Limitations to our study include the small propor-
tion of included studies that were reported after
publication of the QUADAS tool and the overall poor
reporting standard of the included papers. As a true
assessment of a study’s methodological quality relies on
good reporting, we have to conclude that the poor
methodological quality of the papers in this review may
actually reflect a combination of poor study design as
well as poor reporting. Our investigation into the effect
of individual items of study quality on diagnostic accu-
racy could find no significant relationship between any
individual quality item and accuracy. Although we could
demonstrate an improvement in methodological quality
since the introduction of QUADAS we cannot conclude
that this improvement is due to the QUADAS initiative
or due to other factors such as a historical progression
in improved methodological techniques.
Conclusion
We would recommend that all future test accuracy stu-
dies adhere to the QUADAS guidelines and that when
studies are being included in systematic reviews,
reviewers must assess for reporting and methodological
quality using the QUADAS items that are relevant to
their study area and consider additional items where
necessary. As adherence to QUADAS becomes more
widespread, the effect of items of methodological quality
on diagnostic accuracy should be reassessed to enable
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Figure 2 Effect of compliance with QUADAS quality item on the ratio of the diagnostic odds ratio in studies of test accuracy in
obstetrics and gynaecology.
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clinicians to interpret the validity and generalisability of
results. This type of research will also help to improve
test accuracy study design.
Additional material
Additional file 1: Supplemental file 1 - QUADAS checklist. The quality
assessment of studies of diagnostic accuracy checklist with description of
checklist items.
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